Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection

BACKGROUND: A Phase 2a, open-label study (NCT01724086) was conducted to assess the efficacy and safety of a once-daily, 2-direct-acting-antiviral-agent (2-DAA) combination of simeprevir + TMC647055/ritonavir ± ribavirin and of the 3-DAA combination of simeprevir + TMC647055/ritonavir + JNJ-56914845...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:BMC Gastroenterol
Autori principali: Bourgeois, Stefan, Van Vlierberghe, Hans, Moreno, Christophe, Orlent, Hans, Nevens, Frederik, Arastéh, Keikawus, Horsmans, Yves, Schattenberg, Jörn M., Buggisch, Peter, Francque, Sven, Vijgen, Leen, Kakuda, Thomas N., Hoeben, Eva, Luo, Donghan, Vandebosch, An, Jacquemyn, Bert, Van Remoortere, Pieter, Verloes, René
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2017
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5303260/
https://ncbi.nlm.nih.gov/pubmed/28187751
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12876-017-0580-2
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi